Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
oral drug delivery
Biotech
Argenx inks $1.15B Unnatural Products buyout for oral peptides
Argenx has struck a deal to acquire Unnatural Products for $550 million upfront, snapping up the Merck & Co.- and Novartis-partnered biotech.
Nick Paul Taylor
Nov 9, 2026 3:19am
Gilead to buy PepStar’s oral IL-23 drug for $1.3B upfront
Oct 23, 2026 9:00am
Verdiva axes GLP-1 switching trial over ‘market evolution’
Oct 14, 2026 10:13am
Biomea posts data to pitch oral GLP-1 to potential partners
Oct 14, 2026 9:23am
Nortiva purrs into action with long-acting Lynx platform
Jun 18, 2026 8:00am
OrbiMed-backed Pinnacle adds $89M for oral peptides
Mar 26, 2026 10:29am